Summary

The global vaccines market is experiencing steady growth, driven by increasing awareness of preventive healthcare, rising prevalence of infectious diseases, and advancements in vaccine technology. Vaccines have become an essential component of public health strategies worldwide, significantly reducing illness and mortality from viral, bacterial, and other infectious diseases. According to recent market projections, the global vaccines market is expected to expand from USD 76.8 billion in 2026 to USD 117 billion by 2033, reflecting a compound annual growth rate (CAGR) of 6.2% during the forecast period.

The COVID-19 pandemic highlighted the crucial role vaccines play in global health systems. It accelerated research, development, and distribution of vaccines, prompting investments in innovative platforms such as mRNA, viral vector, and recombinant vaccines. These technological advancements are reshaping immunization programs, making vaccines more effective and widely accessible across diverse populations.

Market Insights

The vaccines market is highly diverse, offering products across various disease indications, age groups, and delivery methods. Government-led immunization programs, public-private partnerships, and global initiatives are key factors driving adoption, particularly in emerging economies. Rising healthcare expenditure, improved cold chain logistics, and increasing public awareness of preventive healthcare are further contributing to market growth.

Emerging infectious diseases and recurrent viral outbreaks continue to fuel demand for vaccines. Companies are increasingly focusing on next-generation vaccines, combination therapies, and innovative delivery systems to enhance coverage and compliance. Additionally, the aging population in developed regions is creating new demand for vaccines targeting adults and geriatric patients, expanding the market beyond pediatric immunization.

Market Drivers

Several critical factors are propelling the vaccines market forward:

1. Growing Burden of Infectious Diseases: Widespread viral and bacterial infections, including influenza, COVID-19, pneumococcal diseases, and measles, are driving global demand for effective vaccines.

2. Technological Innovations: Breakthroughs such as mRNA vaccines, viral vectors, and recombinant vaccines are improving safety, efficacy, and production speed, leading to greater adoption.

3. Government and NGO Initiatives: National immunization programs, international collaborations, and financial support from governments and health organizations are improving vaccine accessibility, particularly in developing regions.

4. Rising Public Awareness: Education campaigns and outreach programs are increasing understanding of the benefits of vaccination, promoting higher compliance across different demographics.

5. Pandemic Preparedness: The global response to COVID-19 highlighted the importance of vaccines in pandemic management, accelerating research, regulatory approvals, and manufacturing capacity.

Business Opportunities

The vaccines market presents lucrative opportunities for pharmaceutical and biotechnology companies. Firms investing in research and development of advanced vaccine platforms, including mRNA, viral vectors, and combination vaccines, are poised for growth. Strategic collaborations with governments, healthcare providers, and international health organizations offer avenues for market expansion in emerging economies.

Personalized vaccines, targeting high-risk populations or specific age groups, represent a growing area of innovation. Additionally, investments in cold chain infrastructure, logistics, and digital health platforms for vaccine monitoring can provide companies with a competitive edge. Mergers, acquisitions, and licensing agreements continue to shape the competitive landscape, allowing faster development and distribution of vaccines globally.

Regional Analysis

The vaccines market shows distinct growth patterns across regions:

• North America dominates the market, driven by advanced healthcare infrastructure, high healthcare spending, and robust research and development capabilities.

• Europe is witnessing consistent growth due to comprehensive vaccination policies, innovation in vaccine technologies, and strong public health initiatives.

• Asia Pacific is projected to register the highest growth rate, fueled by rising population, expanding healthcare access, and increasing awareness of preventive healthcare.

• Latin America shows moderate growth, supported by government immunization programs and partnerships with global health organizations.

• Middle East & Africa is gradually adopting vaccines due to improving healthcare infrastructure and investments in public health, despite challenges related to access and affordability.

Key Players

The global vaccines market is highly competitive, with several established companies driving innovation and expanding market reach. Leading players include:

• Pfizer Inc.

• Merck & Co., Inc. (MSD)

• GlaxoSmithKline plc (GSK)

• Sanofi S.A. (Sanofi Pasteur)

• Moderna, Inc.

• Johnson & Johnson

• AstraZeneca plc

• Serum Institute of India Pvt. Ltd.

• BioNTech SE

• CSL Seqirus (CSL Limited)

• Bavarian Nordic

• Bharat Biotech International Ltd.

• China National Biotec Group (CNBG)

• Novavax, Inc.

• Takeda Pharmaceutical Company Limited

These companies are leveraging strategic partnerships, technological advancements, and global distribution networks to strengthen their market presence. Continuous innovation in vaccine development, combined with expansion into emerging markets, is expected to drive competitive advantage.

Segmentation

The vaccines market can be segmented based on type, route of administration, disease indication, age group, distribution channel, and region:

By Type

• Live Attenuated

• Inactivated

• Recombinant/Conjugate/Subunit

• mRNA Vaccine

• Viral Vectors Vaccines

• Toxoid

• Others

By Route of Administration

• Parenteral

• Oral

By Disease Indication

• Viral Diseases

• Bacterial Diseases

By Age Group

• Pediatric

• Adults

By Distribution Channel

• Hospital & Retail Pharmacies

• Government Suppliers

• Others

By Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Vaccines Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2026
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. COVID-19 Impact Analysis
2.5. Porter's Fiver Forces Analysis
2.6. Impact of Russia-Ukraine Conflict
2.7. PESTLE Analysis
2.8. Regulatory Analysis
2.9. Price Trend Analysis
2.9.1. Current Prices and Future Projections, 2025-2033
2.9.2. Price Impact Factors
3. Global Vaccines Market Outlook, 2020 - 2033
3.1. Global Vaccines Market Outlook, by Type, Value (US$ Bn), 2020-2033
3.1.1. Live Attenuated
3.1.2. Inactivated
3.1.3. Recombinant/Conjugate/Subunit
3.1.4. mRNA Vaccine
3.1.5. Viral Vectors Vaccines
3.1.6. Toxoid
3.1.7. Others
3.2. Global Vaccines Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
3.2.1. Parenteral
3.2.2. Oral
3.3. Global Vaccines Market Outlook, by Disease Indication, Value (US$ Bn), 2020-2033
3.3.1. Viral Diseases
3.3.2. Bacterial Diseases
3.4. Global Vaccines Market Outlook, by Age Group, Value (US$ Bn), 2020-2033
3.4.1. Pediatric
3.4.2. Adults
3.5. Global Vaccines Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
3.5.1. Hospital & Retail Pharmacies
3.5.2. Government Suppliers
3.5.3. Others
3.6. Global Vaccines Market Outlook, by Region, Value (US$ Bn), 2020-2033
3.6.1. North America
3.6.2. Europe
3.6.3. Asia Pacific
3.6.4. Latin America
3.6.5. Middle East & Africa
4. North America Vaccines Market Outlook, 2020 - 2033
4.1. North America Vaccines Market Outlook, by Type, Value (US$ Bn), 2020-2033
4.1.1. Live Attenuated
4.1.2. Inactivated
4.1.3. Recombinant/Conjugate/Subunit
4.1.4. mRNA Vaccine
4.1.5. Viral Vectors Vaccines
4.1.6. Toxoid
4.1.7. Others
4.2. North America Vaccines Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
4.2.1. Parenteral
4.2.2. Oral
4.3. North America Vaccines Market Outlook, by Disease Indication, Value (US$ Bn), 2020-2033
4.3.1. Viral Diseases
4.3.2. Bacterial Diseases
4.4. North America Vaccines Market Outlook, by Age Group, Value (US$ Bn), 2020-2033
4.4.1. Pediatric
4.4.2. Adults
4.5. North America Vaccines Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
4.5.1. Hospital & Retail Pharmacies
4.5.2. Government Suppliers
4.5.3. Others
4.6. North America Vaccines Market Outlook, by Country, Value (US$ Bn), 2020-2033
4.6.1. U.S. Vaccines Market Outlook, by Type, 2020-2033
4.6.2. U.S. Vaccines Market Outlook, by Route of Administration, 2020-2033
4.6.3. U.S. Vaccines Market Outlook, by Disease Indication, 2020-2033
4.6.4. U.S. Vaccines Market Outlook, by Age Group, 2020-2033
4.6.5. U.S. Vaccines Market Outlook, by Distribution Channel, 2020-2033
4.6.6. Canada Vaccines Market Outlook, by Type, 2020-2033
4.6.7. Canada Vaccines Market Outlook, by Route of Administration, 2020-2033
4.6.8. Canada Vaccines Market Outlook, by Disease Indication, 2020-2033
4.6.9. Canada Vaccines Market Outlook, by Age Group, 2020-2033
4.6.10. Canada Vaccines Market Outlook, by Distribution Channel, 2020-2033
4.7. BPS Analysis/Market Attractiveness Analysis
5. Europe Vaccines Market Outlook, 2020 - 2033
5.1. Europe Vaccines Market Outlook, by Type, Value (US$ Bn), 2020-2033
5.1.1. Live Attenuated
5.1.2. Inactivated
5.1.3. Recombinant/Conjugate/Subunit
5.1.4. mRNA Vaccine
5.1.5. Viral Vectors Vaccines
5.1.6. Toxoid
5.1.7. Others
5.2. Europe Vaccines Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
5.2.1. Parenteral
5.2.2. Oral
5.3. Europe Vaccines Market Outlook, by Disease Indication, Value (US$ Bn), 2020-2033
5.3.1. Viral Diseases
5.3.2. Bacterial Diseases
5.4. Europe Vaccines Market Outlook, by Age Group, Value (US$ Bn), 2020-2033
5.4.1. Pediatric
5.4.2. Adults
5.5. Europe Vaccines Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
5.5.1. Hospital & Retail Pharmacies
5.5.2. Government Suppliers
5.5.3. Others
5.6. Europe Vaccines Market Outlook, by Country, Value (US$ Bn), 2020-2033
5.6.1. Germany Vaccines Market Outlook, by Type, 2020-2033
5.6.2. Germany Vaccines Market Outlook, by Route of Administration, 2020-2033
5.6.3. Germany Vaccines Market Outlook, by Disease Indication, 2020-2033
5.6.4. Germany Vaccines Market Outlook, by Age Group, 2020-2033
5.6.5. Germany Vaccines Market Outlook, by Distribution Channel, 2020-2033
5.6.6. Italy Vaccines Market Outlook, by Type, 2020-2033
5.6.7. Italy Vaccines Market Outlook, by Route of Administration, 2020-2033
5.6.8. Italy Vaccines Market Outlook, by Disease Indication, 2020-2033
5.6.9. Italy Vaccines Market Outlook, by Age Group, 2020-2033
5.6.10. Italy Vaccines Market Outlook, by Distribution Channel, 2020-2033
5.6.11. France Vaccines Market Outlook, by Type, 2020-2033
5.6.12. France Vaccines Market Outlook, by Route of Administration, 2020-2033
5.6.13. France Vaccines Market Outlook, by Disease Indication, 2020-2033
5.6.14. France Vaccines Market Outlook, by Age Group, 2020-2033
5.6.15. France Vaccines Market Outlook, by Distribution Channel, 2020-2033
5.6.16. U.K. Vaccines Market Outlook, by Type, 2020-2033
5.6.17. U.K. Vaccines Market Outlook, by Route of Administration, 2020-2033
5.6.18. U.K. Vaccines Market Outlook, by Disease Indication, 2020-2033
5.6.19. U.K. Vaccines Market Outlook, by Age Group, 2020-2033
5.6.20. U.K. Vaccines Market Outlook, by Distribution Channel, 2020-2033
5.6.21. Spain Vaccines Market Outlook, by Type, 2020-2033
5.6.22. Spain Vaccines Market Outlook, by Route of Administration, 2020-2033
5.6.23. Spain Vaccines Market Outlook, by Disease Indication, 2020-2033
5.6.24. Spain Vaccines Market Outlook, by Age Group, 2020-2033
5.6.25. Spain Vaccines Market Outlook, by Distribution Channel, 2020-2033
5.6.26. Russia Vaccines Market Outlook, by Type, 2020-2033
5.6.27. Russia Vaccines Market Outlook, by Route of Administration, 2020-2033
5.6.28. Russia Vaccines Market Outlook, by Disease Indication, 2020-2033
5.6.29. Russia Vaccines Market Outlook, by Age Group, 2020-2033
5.6.30. Russia Vaccines Market Outlook, by Distribution Channel, 2020-2033
5.6.31. Rest of Europe Vaccines Market Outlook, by Type, 2020-2033
5.6.32. Rest of Europe Vaccines Market Outlook, by Route of Administration, 2020-2033
5.6.33. Rest of Europe Vaccines Market Outlook, by Disease Indication, 2020-2033
5.6.34. Rest of Europe Vaccines Market Outlook, by Age Group, 2020-2033
5.6.35. Rest of Europe Vaccines Market Outlook, by Distribution Channel, 2020-2033
5.7. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Vaccines Market Outlook, 2020 - 2033
6.1. Asia Pacific Vaccines Market Outlook, by Type, Value (US$ Bn), 2020-2033
6.1.1. Live Attenuated
6.1.2. Inactivated
6.1.3. Recombinant/Conjugate/Subunit
6.1.4. mRNA Vaccine
6.1.5. Viral Vectors Vaccines
6.1.6. Toxoid
6.1.7. Others
6.2. Asia Pacific Vaccines Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
6.2.1. Parenteral
6.2.2. Oral
6.3. Asia Pacific Vaccines Market Outlook, by Disease Indication, Value (US$ Bn), 2020-2033
6.3.1. Viral Diseases
6.3.2. Bacterial Diseases
6.4. Asia Pacific Vaccines Market Outlook, by Age Group, Value (US$ Bn), 2020-2033
6.4.1. Pediatric
6.4.2. Adults
6.5. Asia Pacific Vaccines Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
6.5.1. Hospital & Retail Pharmacies
6.5.2. Government Suppliers
6.5.3. Others
6.6. Asia Pacific Vaccines Market Outlook, by Country, Value (US$ Bn), 2020-2033
6.6.1. China Vaccines Market Outlook, by Type, 2020-2033
6.6.2. China Vaccines Market Outlook, by Route of Administration, 2020-2033
6.6.3. China Vaccines Market Outlook, by Disease Indication, 2020-2033
6.6.4. China Vaccines Market Outlook, by Age Group, 2020-2033
6.6.5. China Vaccines Market Outlook, by Distribution Channel, 2020-2033
6.6.6. Japan Vaccines Market Outlook, by Type, 2020-2033
6.6.7. Japan Vaccines Market Outlook, by Route of Administration, 2020-2033
6.6.8. Japan Vaccines Market Outlook, by Disease Indication, 2020-2033
6.6.9. Japan Vaccines Market Outlook, by Age Group, 2020-2033
6.6.10. Japan Vaccines Market Outlook, by Distribution Channel, 2020-2033
6.6.11. South Korea Vaccines Market Outlook, by Type, 2020-2033
6.6.12. South Korea Vaccines Market Outlook, by Route of Administration, 2020-2033
6.6.13. South Korea Vaccines Market Outlook, by Disease Indication, 2020-2033
6.6.14. South Korea Vaccines Market Outlook, by Age Group, 2020-2033
6.6.15. South Korea Vaccines Market Outlook, by Distribution Channel, 2020-2033
6.6.16. India Vaccines Market Outlook, by Type, 2020-2033
6.6.17. India Vaccines Market Outlook, by Route of Administration, 2020-2033
6.6.18. India Vaccines Market Outlook, by Disease Indication, 2020-2033
6.6.19. India Vaccines Market Outlook, by Age Group, 2020-2033
6.6.20. India Vaccines Market Outlook, by Distribution Channel, 2020-2033
6.6.21. Southeast Asia Vaccines Market Outlook, by Type, 2020-2033
6.6.22. Southeast Asia Vaccines Market Outlook, by Route of Administration, 2020-2033
6.6.23. Southeast Asia Vaccines Market Outlook, by Disease Indication, 2020-2033
6.6.24. Southeast Asia Vaccines Market Outlook, by Age Group, 2020-2033
6.6.25. Southeast Asia Vaccines Market Outlook, by Distribution Channel, 2020-2033
6.6.26. Rest of SAO Vaccines Market Outlook, by Type, 2020-2033
6.6.27. Rest of SAO Vaccines Market Outlook, by Route of Administration, 2020-2033
6.6.28. Rest of SAO Vaccines Market Outlook, by Disease Indication, 2020-2033
6.6.29. Rest of SAO Vaccines Market Outlook, by Age Group, 2020-2033
6.6.30. Rest of SAO Vaccines Market Outlook, by Distribution Channel, 2020-2033
6.7. BPS Analysis/Market Attractiveness Analysis
7. Latin America Vaccines Market Outlook, 2020 - 2033
7.1. Latin America Vaccines Market Outlook, by Type, Value (US$ Bn), 2020-2033
7.1.1. Live Attenuated
7.1.2. Inactivated
7.1.3. Recombinant/Conjugate/Subunit
7.1.4. mRNA Vaccine
7.1.5. Viral Vectors Vaccines
7.1.6. Toxoid
7.1.7. Others
7.2. Latin America Vaccines Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
7.2.1. Parenteral
7.2.2. Oral
7.3. Latin America Vaccines Market Outlook, by Disease Indication, Value (US$ Bn), 2020-2033
7.3.1. Viral Diseases
7.3.2. Bacterial Diseases
7.4. Latin America Vaccines Market Outlook, by Age Group, Value (US$ Bn), 2020-2033
7.4.1. Pediatric
7.4.2. Adults
7.5. Latin America Vaccines Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
7.5.1. Hospital & Retail Pharmacies
7.5.2. Government Suppliers
7.5.3. Others
7.6. Latin America Vaccines Market Outlook, by Country, Value (US$ Bn), 2020-2033
7.6.1. Brazil Vaccines Market Outlook, by Type, 2020-2033
7.6.2. Brazil Vaccines Market Outlook, by Route of Administration, 2020-2033
7.6.3. Brazil Vaccines Market Outlook, by Disease Indication, 2020-2033
7.6.4. Brazil Vaccines Market Outlook, by Age Group, 2020-2033
7.6.5. Brazil Vaccines Market Outlook, by Distribution Channel, 2020-2033
7.6.6. Mexico Vaccines Market Outlook, by Type, 2020-2033
7.6.7. Mexico Vaccines Market Outlook, by Route of Administration, 2020-2033
7.6.8. Mexico Vaccines Market Outlook, by Disease Indication, 2020-2033
7.6.9. Mexico Vaccines Market Outlook, by Age Group, 2020-2033
7.6.10. Mexico Vaccines Market Outlook, by Distribution Channel, 2020-2033
7.6.11. Argentina Vaccines Market Outlook, by Type, 2020-2033
7.6.12. Argentina Vaccines Market Outlook, by Route of Administration, 2020-2033
7.6.13. Argentina Vaccines Market Outlook, by Disease Indication, 2020-2033
7.6.14. Argentina Vaccines Market Outlook, by Age Group, 2020-2033
7.6.15. Argentina Vaccines Market Outlook, by Distribution Channel, 2020-2033
7.6.16. Rest of LATAM Vaccines Market Outlook, by Type, 2020-2033
7.6.17. Rest of LATAM Vaccines Market Outlook, by Route of Administration, 2020-2033
7.6.18. Rest of LATAM Vaccines Market Outlook, by Disease Indication, 2020-2033
7.6.19. Rest of LATAM Vaccines Market Outlook, by Age Group, 2020-2033
7.6.20. Rest of LATAM Vaccines Market Outlook, by Distribution Channel, 2020-2033
7.7. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Vaccines Market Outlook, 2020 - 2033
8.1. Middle East & Africa Vaccines Market Outlook, by Type, Value (US$ Bn), 2020-2033
8.1.1. Live Attenuated
8.1.2. Inactivated
8.1.3. Recombinant/Conjugate/Subunit
8.1.4. mRNA Vaccine
8.1.5. Viral Vectors Vaccines
8.1.6. Toxoid
8.1.7. Others
8.2. Middle East & Africa Vaccines Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
8.2.1. Parenteral
8.2.2. Oral
8.3. Middle East & Africa Vaccines Market Outlook, by Disease Indication, Value (US$ Bn), 2020-2033
8.3.1. Viral Diseases
8.3.2. Bacterial Diseases
8.4. Middle East & Africa Vaccines Market Outlook, by Age Group, Value (US$ Bn), 2020-2033
8.4.1. Pediatric
8.4.2. Adults
8.5. Middle East & Africa Vaccines Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
8.5.1. Hospital & Retail Pharmacies
8.5.2. Government Suppliers
8.5.3. Others
8.6. Middle East & Africa Vaccines Market Outlook, by Country, Value (US$ Bn), 2020-2033
8.6.1. GCC Vaccines Market Outlook, by Type, 2020-2033
8.6.2. GCC Vaccines Market Outlook, by Route of Administration, 2020-2033
8.6.3. GCC Vaccines Market Outlook, by Disease Indication, 2020-2033
8.6.4. GCC Vaccines Market Outlook, by Age Group, 2020-2033
8.6.5. GCC Vaccines Market Outlook, by Distribution Channel, 2020-2033
8.6.6. South Africa Vaccines Market Outlook, by Type, 2020-2033
8.6.7. South Africa Vaccines Market Outlook, by Route of Administration, 2020-2033
8.6.8. South Africa Vaccines Market Outlook, by Disease Indication, 2020-2033
8.6.9. South Africa Vaccines Market Outlook, by Age Group, 2020-2033
8.6.10. South Africa Vaccines Market Outlook, by Distribution Channel, 2020-2033
8.6.11. Egypt Vaccines Market Outlook, by Type, 2020-2033
8.6.12. Egypt Vaccines Market Outlook, by Route of Administration, 2020-2033
8.6.13. Egypt Vaccines Market Outlook, by Disease Indication, 2020-2033
8.6.14. Egypt Vaccines Market Outlook, by Age Group, 2020-2033
8.6.15. Egypt Vaccines Market Outlook, by Distribution Channel, 2020-2033
8.6.16. Nigeria Vaccines Market Outlook, by Type, 2020-2033
8.6.17. Nigeria Vaccines Market Outlook, by Route of Administration, 2020-2033
8.6.18. Nigeria Vaccines Market Outlook, by Disease Indication, 2020-2033
8.6.19. Nigeria Vaccines Market Outlook, by Age Group, 2020-2033
8.6.20. Nigeria Vaccines Market Outlook, by Distribution Channel, 2020-2033
8.6.21. Rest of Middle East Vaccines Market Outlook, by Type, 2020-2033
8.6.22. Rest of Middle East Vaccines Market Outlook, by Route of Administration, 2020-2033
8.6.23. Rest of Middle East Vaccines Market Outlook, by Disease Indication, 2020-2033
8.6.24. Rest of Middle East Vaccines Market Outlook, by Age Group, 2020-2033
8.6.25. Rest of Middle East Vaccines Market Outlook, by Distribution Channel, 2020-2033
8.7. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Vs Segment Heatmap
9.2. Company Market Share Analysis, 2025
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Pfizer Inc.
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Developments
9.4.2. Merck & Co., Inc. (MSD)
9.4.3. GlaxoSmithKline plc (GSK)
9.4.4. Sanofi S.A. (Sanofi Pasteur)
9.4.5. Moderna, Inc.
9.4.6. Johnson & Johnson
9.4.7. AstraZeneca plc
9.4.8. Serum Institute of India Pvt. Ltd.
9.4.9. BioNTech SE
9.4.10. CSL Seqirus (CSL Limited)
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations